Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Katheryn Santos
Observed name:
K. Santos
Institutions:
Broad Institute,
Dana-Farber Cancer Institute
Observed institutions:
Broad Institute,
Boston Children's Hospital,
Harvard University,
Baylor College of Medicine,
Yale Cancer Center,
Dana-Farber Cancer Institute,
Dana-Farber Brigham Cancer Center
show all 7
ORCID:
0000-0002-3945-7644
Observed ORCID:
0000-0002-3945-7644
OpenAlex ID:
A5102799583
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
2022
·
Marla Lipsyc-Sharf
, Elza C. de Bruin
, et al.
·
Journal of Clinical Oncology
·
172
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
2022
·
Anna-Lisa Doebley
, Minjeong Ko
, et al.
·
Nature Communications
·
157
PDF
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
2023
·
H.A. Parsons
, T. Blewett
, et al.
·
Annals of Oncology
·
88
PDF
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer
2024
·
Stefania Morganti
, Christopher J. Gibson
, et al.
·
Journal of Clinical Oncology
·
46
PDF
A Device for the Quantification of Oxygen Consumption and Caloric Expenditure in the Neonatal Range
2018
·
Einav Nachman
, Peter Clemensen
, et al.
·
Anesthesia & Analgesia
·
8
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).
2022
·
Marla Lipsyc-Sharf
, Elza De Bruin
, et al.
·
Journal of Clinical Oncology
·
7
Abstract 3874: Genomic mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in HER2+ metastatic breast cancer (HER2+ MBC)
2023
·
Heather A. Parsons
, Conor Messer
, et al.
·
Cancer Research
·
6
Abstract PS5-11: Ultrasensitive ctDNA Tracking Predicts Exceptional Response in HER2+ Metastatic Breast Cancer
2026
·
S. Morganti
, C. Song
, et al.
·
Clinical Cancer Research
·
4
Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer
2024
·
Shoshana M. Rosenberg
, Yue Zheng
, et al.
·
Breast Cancer Research and Treatment
·
3
Abstract PO2-04-01: Predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer
2024
·
Stefania Morganti
, Tianyu Li
, et al.
·
Cancer Research
·
3
Abstract PS2-07-06: Prevalence and dynamics of circulating tumor DNA among patients with triple-negative breast cancer undergoing preoperative systemic therapy with or without immunotherapy
2026
·
T. R. Yoo
, S. Morganti
, et al.
·
Clinical Cancer Research
·
2
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA
2025
·
Heather A. Parsons
, Conor Messer
, et al.
·
Cell Genomics
·
2
Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.
2025
·
Tae-Kyung Robyn Yoo
, Hillary Heiling
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Abstract PD7-02: Transcriptomic profiling of the tumor microenvironment indicates differential response to neoadjuvant chemotherapy with and without pembrolizumab in early TNBC
2026
·
J. Gomez Tejeda Zanudo
, S. Kirschner
, et al.
·
Clinical Cancer Research
·
1
Abstract PD2-09: Convergent genomic evolution from early to lethal HR+/HER2- metastatic breast cancer
2026
·
N. Priedigkeit
, M. E. Hughes
, et al.
·
Clinical Cancer Research
·
1
Abstract PS2-07-16: Clinicogenomic characterization and ctDNA detection of ESR1 fusion positive metastatic breast cancer
2026
·
K. Santos
, A. Lebrón-Torres
, et al.
·
Clinical Cancer Research
·
1
Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030
2023
·
Heather A. Parsons
, Timothy Blewett
, et al.
·
Cancer Research
·
1
Author Correction: A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
2023
·
Anna-Lisa Doebley
, Minjeong Ko
, et al.
·
Nature Communications
·
1
PDF
Cltr-08 Treatment Strategies in Metastatic Breast Cancer Patients With Leptomeningeal Disease – a Prospective Observational Registry Study
2026
·
Angelika M Starzer
, Katheryn Santos
, et al.
·
Neuro-Oncology Advances
PDF
Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer
2026
·
Megan E. Tesch
, Noah Graham
, et al.
·
Breast Cancer Research and Treatment
Abstract 1020: Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC)
2026
·
Stefania Morganti
, Jonathan Beagan
, et al.
·
Cancer Research
Abstract PS4-07-18: Association of tumor-infiltrating lymphocytes (TILs) with outcomes in patients with early TNBC treated with neoadjuvant chemotherapy with or without pembrolizumab
2026
·
R. S. Lee
, Q. Jin
, et al.
·
Clinical Cancer Research
Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancer
2024
·
Heather Parsons
, Conor Messer
, et al.
·
Research Square
PDF
Abstract P5-14-03: Clonal hematopoiesis of indeterminate potential after (neo)adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study
2023
·
Stefania Morganti
, Qingchun Jin
, et al.
·
Cancer Research
Abstract P6-05-05: Patient-reported outcomes, perceptions, and knowledge about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC)
2023
·
Shoshana Rosenberg
, Yue Zheng
, et al.
·
Cancer Research
Show more works
View as search
Works count:
27
Citation count:
505
H-index:
6
I10-index:
4
Year
Topic
Type